Niki BioSolutions weighs financing options as going-concern warning clouds post-merger outlook

Aptorum

21/08/2026 22:15

Overview
US biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6
Operating expenses for H1 rose sharply compared to prior year
Company completed merger and domestication, now named Niki BioSolutions

Outlook
Company says substantial doubt exists about ability to continue as a going concern over next year

Result Drivers
HIGHER OPERATING EXPENSES - Co said operating expenses rose sharply, driven by increased research and development, general and administrative, and legal costs
GOING CONCERN RISKS - Co flagged substantial doubt about ability to continue as a going concern due to recurring losses and negative cash flows

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Loss Per Basic Share
 
$1.60
 

Reuters Recommended Reads
Aug 20 - China's Brii Biosciences interim net loss narrows on lower R&D expenses
Aug 21 - Biotech firm Antengene's H1 revenue jumps on licensing deals
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)